News | August 4, 2014

Kapa Biosystems Strengthens Investment Across Asia Pacific Region By Extending Exclusive Japanese Distribution Agreement With Nippon Genetics

WILMINGTON, MASS.--(BUSINESS WIRE)--

Kapa Biosystems announced today that it has signed a new three-year exclusive distribution agreement with Nippon Genetics Co., Ltd., further extending the successful seven-year relationship between the companies and enabling Nippon Genetics to continue marketing, distributing, and servicing Kapa Biosystems’ genomics reagents in Japan. This agreement is a key part of Kapa Biosystems corporate growth strategy and the first of several key commercial announcements that will be made later this year.

Kapa Biosystems offers a portfolio of advanced reagents for use in PCR, qPCR, next-generation sequencing, and molecular diagnostics applications. The reagents contain novel enzymes—engineered via directed evolution—that confer significant performance advantages when compared to traditional wild-type enzymes. Many of the products are optimized for challenging samples and high-throughput workflows, and include pre-validated scripts using the leading liquid-handling automation platforms.

“The genetic research and applied markets in Japan are growing exponentially and many scientists rely on us to deliver high-quality and reliable solutions,” said Kazuo Yamazaki, CEO and President, Nippon Genetics Co., Ltd. “Kapa Biosystems products fit perfectly within our innovative life science offerings and enable us to provide more complete solutions to our customers.”

Over the past year, Kapa Biosystems has added several proven industry veterans to its management team and more than doubled the company’s previous facility investment to scale enzyme production, quality control, and manufacturing capacity across its various business franchises. Over the next few months, the company plans on announcing several other key distribution agreements and corporate initiatives to better support the growing number of customers around the world.

“With more than 25 years of experience working with cutting edge technologies and strong relationships with the key opinion leaders in Japan, Nippon Genetics is the ideal distribution partner for our business,” said Jean-Christophe Hatinguais, Director of International Sales, Kapa Biosystems. “We are seeing broad adoption and strong demand for our innovative products not only in Japan, but across the Asia Pacific, European, and North American regions. We are now focused on extending our global reach by increasing our strategic investments and expanding our distribution network in key markets.”

About Nippon Genetics Co., Ltd.

Nippon Genetics is a marketing and distribution company for the life science markets in Japan. Headquartered in Tokyo, the company provides a wide range of genomic and molecular biology research products and services related to nucleic acid separation/purification, electrophoresis, PCR, real-time PCR, and library preparation for next-generation sequencing. The company uses its own laboratory to help ensure optimization and reproducible results for various applications. The company has a sales office in Kyoto, and also has an affiliated company in Duren, Germany. For more information, please visit www.n-genetics.com.

About Kapa Biosystems

Kapa Biosystems is a life science reagents supplier that employs proprietary, directed evolution technologies to optimize enzymes for PCR, real-time PCR, next-generation sequencing and molecular diagnostic applications. Kapa Biosystems offers a portfolio of best-in-class products containing novel enzymes that confer significant performance advantages when compared to traditional wild-type enzymes. The company is based in Wilmington, Massachusetts with a research, development, and manufacturing facility in Cape Town, South Africa. For more information, please visit www.kapabiosystems.com.

KAPA is a trademark of Kapa Biosystems. All other product names and trademarks are the property of their respective owners.

Kapa Biosystems’ products are for Research Use Only; not for use in diagnostic procedures.


Copyright Business Wire 2014

Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.